Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.66 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508438 | 0.89 | FFAR1 (0.64) | FFAR1MAOBMEN1SLC26A4KMT2A | |
| SCHEMBL1508510 | 0.88 | FFAR1 (0.82) | FFAR1MAOBMEN1SLC26A4KMT2A | |
| SCHEMBL1508558 | 0.87 | FFAR1 (0.66) | FFAR1MAOBMEN1SLC26A4KMT2A | |
| SCHEMBL8770911 | 0.81 | ADRA1A (0.46) | TSHR | |
| SCHEMBL1508081 | 0.80 | FFAR1 (1.00) | FFAR1 | |
| SCHEMBL1508603 | 0.79 | FFAR1 (0.80) | FFAR1MAOBMEN1SLC26A4KMT2A | |
| SCHEMBL1508207 | 0.77 | FFAR1 (0.81) | FFAR1MAOBMEN1SLC26A4KMT2A | |
| SCHEMBL1508273 | 0.77 | FFAR1 (0.67) | FFAR1MRGPRX4TSHRSMN1; SMN2 | |
| SCHEMBL1508496 | 0.75 | FFAR1 (0.67) | FFAR1S1PR1S1PR5MRGPRX4TSHR | |
| SCHEMBL1508523 | 0.74 | FFAR1 (0.80) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222281-B2 | Carboxylic acid compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2289868-A1 | CARBOXYLIC ACID COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2011-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | AKR1C3, SLC5A1, GPR119 | FFAR1 219/4885MAOB 904/4885MEN1 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.